Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkin's Lymphom... (x patients decreased during treatment wi...)

HOME >> MEDICINE >> NEWS

Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkin's Lymphoma Patients

Date:11/29/2007

x patients decreased during treatment with MT103, with a complete clearance of tumor cells from the bone marrow in three patients and partial clearance in the other two patients.

Complete and partial clinical responses were assessed according to Cheson criteria, and all responses were confirmed by a central review. Clinical responses and tumor clearance from the bone marrow demonstrate clinical activity of the BiTE antibody in those patients who received higher doses.

"We are pleased to see the number of objective responses to MT103 in a relapsed patient population, and are looking forward to providing a more detailed update at ASH about our exciting new clinical data with the first BiTE antibody in clinical trials," commented Christian Itin, Ph.D., President and Chief Executive Officer of Micromet.

MT103 is a novel, highly-specific and highly-potent drug, with which objective responses are being seen in patients with FL and MCL who have progressed after multiple prior treatments. The most common adverse events observed in this study were fever, chills, leukopenia, lymphopenia, pyrexia and elevated liver enzymes. The majority of the adverse events have been fully reversible and in many cases resolved without discontinuation of MT103 administration. Less common adverse events included central nervous system events, which were fully reversible after discontinuation of the infusion. Dose escalation continues.

"These clinical responses to MT103 in patients with various B-cell malignancies are an important achievement in our partnership with Micromet,'' commented Dirk Reitsma, M.D., vice president, clinical development, oncology, MedImmune. "The expansion of research into the potential of BiTE technology in a clinical setting represents another pioneering effort by MedImmune to develop novel targeted cancer treatments for patients in need."

About BiTE(R) Antibodies

BiTE(R) antibodies are designed to direct the body's cytotoxic, o
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6
Related medicine news :

1. Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia
2. Micromets BiTE(R) Antibodies Reveal Unique Mode of Action
3. MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist(R)
4. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
5. Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results
6. MedImmune to present RSV surveillance and cost-effectiveness data at American Academy of Pediatrics
7. MedImmune presents new pharmaco-economic data at AAP regarding infants at high risk for RSV
8. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
9. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
10. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
11. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference

Post Your Comments:

Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkin's Lymphom...(x patients decreased during treatment wi...),Health